Abstract 804
Background
A decrease lymphocyte to monocyte ratio (LMR) has been reported to be related with worsen prognosis for certain hematologic and solid malignancies. Also pretreatment LMR is associated with the prognosis of patients with breast cancer. However, relationship between treatment-related low LMR and prognostic impact has not well been investigated in breast cancer. The purpose of this study is to evaluate the relationship between radiotherapy (RT)-induced low LMR and recurrence in patients with breast cancer.
Methods
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Results
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Conclusions
We demonstrated that RT-induced low LMR is a poor prognostic factor for patients with BCS and adjuvant RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract